<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04678934</url>
  </required_header>
  <id_info>
    <org_study_id>CLEVERTAVR202011-01</org_study_id>
    <nct_id>NCT04678934</nct_id>
  </id_info>
  <brief_title>Cerebral Lesion and Neurocognitive Status Changes After TAVR</brief_title>
  <acronym>CLEVER-TAVR</acronym>
  <official_title>Cerebral Lesion and Neurocognitive Status Changes After Transcatheter Aortic Valve Replacement：A Prospective Multicenter Observational Cohort Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Third Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xiangtan Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ZhuZhou Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First People's Hospital of Changde City</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xiangya Changde Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Second Xiangya Hospital of Central South University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The CLEVER-TAVR cohort (Cerebral Lesion and Neurocognitive Status Changes after Transcatheter&#xD;
      Aortic Valve Replacement) is a multicenter observational cohort study. The investigators will&#xD;
      screen consecutive patients ≥65 years of age before TAVR and enroll those that complete the&#xD;
      procedure successfully. The investigators will assess the neurocognitive function using&#xD;
      multiple tests with Reliable Change Index before TAVR and 7, 30, 90, 180 and 360 days after&#xD;
      TAVR. The primary endpoint will be major adverse cardiovascular and cerebral events(MACCE,&#xD;
      defined according to the Valve Academic Research Consortium-2 data dictionary) at 1 year.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design The CLEVER-TAVR cohort (Cerebral Lesion and Neurocognitive Status Changes after&#xD;
      Transcatheter Aortic Valve Replacement) is a multicenter prospective observational study.&#xD;
      Patients with aortic stenosis who successfully undergo TAVR procedure from January 2021 to&#xD;
      December 2021 will be enrolled in this study according to the inclusion criteria.&#xD;
      Preoperative cognitive function, DW-MRI evaluation and baseline data will be recorded. All&#xD;
      patients should be followed up for 1 year, including telephone follow-up once a month to&#xD;
      record the main end-point events, and clinic follow-up at 30, 90, 180, 360 days after TAVR.&#xD;
      Laboratory examination, electrocardiogram, color Doppler ultrasound and other examinations&#xD;
      will be collected and recorded. The changes of cognitive function and brain imaging (DW-MRI)&#xD;
      will be evaluated before discharge(7 days), 30, 90, 180, 360 days after procedure. The&#xD;
      primary endpoint will be major adverse cardiovascular and cerebral events(MACCE), including&#xD;
      all-cause death, stroke, acute kidney injury, myocardial infarction, bleeding complications,&#xD;
      vascular complications, permanent pacemaker implantation, conduction block and arrhythmia,&#xD;
      valve related complications. The postoperative valve function, life quality and other&#xD;
      complications related to TAVR will also be recorded.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>major adverse cardiovascular and cerebral events</measure>
    <time_frame>1 year.</time_frame>
    <description>Defined as VARC-2, major adverse cardiovascular and cerebral events(MACCE), including all-cause death, stroke, acute kidney injury, myocardial infarction, bleeding complications, vascular complications, permanent pacemaker implantation, conduction block and arrhythmia, valve related complications.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cognitive Decline.</measure>
    <time_frame>1 year.</time_frame>
    <description>Cognitive Decline is defined as Mini-mental State Examination(MMSE) score decreased by more than 3 points. The MMSE is a 30-point test, the lower the score, the worse the severity (24-30: No cognitive impairment, 18-23: mild Cognitive impairment, 0-17: severe cognitive impairment).</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Aortic Stenosis</condition>
  <arm_group>
    <arm_group_label>Bicuspid aortic valve subgroup</arm_group_label>
    <description>For analysis in Bicuspid aortic valve population.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TAVR</intervention_name>
    <description>Transcatheter aortic valve replacement</description>
    <arm_group_label>Bicuspid aortic valve subgroup</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, stool&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with aortic stenosis who successfully undergo TAVR procedure in 8 centers of&#xD;
        China.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients voluntarily participated and signed informed consent;&#xD;
&#xD;
               -  Patients with severe aortic stenosis undergo TAVR after assessment by the Heart&#xD;
                  Team; [Definition of severe aortic stenosis: mean aortic pressure gradient (MPG)&#xD;
                  ≥ 40 mmHg, aortic valve area (AVA) ≤ 1.0 cm2 and maximal aortic velocity (Vmax) ≥&#xD;
                  4 m / s.] ③ Age ≥ 65 years old.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Emergency procedure;&#xD;
&#xD;
               -  Severe cognitive impairment (MMSE &lt; 15), or years of education &lt; 6 years;&#xD;
&#xD;
                    -  Unstable condition (intractable angina pectoris, acute heart failure) or&#xD;
                       patients can not complete MRI examination or cognitive assessment;&#xD;
&#xD;
                         -  TAVR operation failed or transferred to surgery for SAVR due to serious&#xD;
                            complications; ⑤ Speech disorders, or mental disorders, or severe&#xD;
                            physical disorders (MRS ≥ 3); ⑥ Patients with complicated congenital&#xD;
                            heart disease, HCM, surgery valve replacement or combined valvular&#xD;
                            disease; ⑦ Patients with life expectancy less than 12 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shenghua Zhou</last_name>
    <role>Principal Investigator</role>
    <affiliation>Second xiangya Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shenghua Zhou</last_name>
    <phone>+8673185292012</phone>
    <email>zhoushenghua@csu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhenfei Fang</last_name>
    <phone>+8613308487909</phone>
    <email>fangzhenfei@csu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Second Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 17, 2020</study_first_submitted>
  <study_first_submitted_qc>December 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 22, 2020</study_first_posted>
  <last_update_submitted>December 22, 2020</last_update_submitted>
  <last_update_submitted_qc>December 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Second Xiangya Hospital of Central South University</investigator_affiliation>
    <investigator_full_name>Shenghua Zhou</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

